Browsing by Author "Ríos Raggio, Mariana"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Concanavalin-A Induces Granulosa Cell Death and Inhibits FSH-Mediated Follicular Growth and Ovarian Maturation in Female Rats
    (2013) Velásquez Opazo, Ethel Virginia; Ríos Raggio, Mariana; Ortíz Scarlazetta, María Elena; Lizama, Carlos; Orge, Felipe; Oliva, Barbara; Orellana Walden, Renán Felipe; Villalón, Manuel J.; Moreno Mauro, Ricardo D.; Owen, Gareth Ivor; Núñez, Elizabeth; Abramovich, Dalhia; Tesone, Marta, Rokka, Anne; Corthals, Garry; Croxatto A., Horacio; Parborell, Fernanda
  • No Thumbnail Available
    Item
    Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
    (2022) Galvez Arriagada, Nicolás Marcelo Salvador; Pacheco Ruidiaz, Gaspar Andrés; Schültz Lombardic, Barbara Melinka; Melo González, Felipe Andrés; Soto Ramírez, Jorge Andrés; Duarte Peñaloza, Luisa Fernanda; González Carreño, Liliana Andrea; Rivera Pérez, Daniela Belén; Ríos Raggio, Mariana; Berríos, Roslye V.; Vazquéz Hernandéz, Yaneisi; Moreno Tapia, Daniela Paz; Vallejos Galvez, Omar Patricio; Andrade Parra, Catalina Andrea; Hoppe Elsholz, Guillermo; Iturriaga, Carolina; Urzua, Marcela; Navarrete, María S.; Rojas González, Álvaro Miguel; Fasce Pineda, Rodrigo Andrés; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Gaete Argel, Aracelly; Acevedo Blanco, Mónica Andrea; Valiente Echeverría, Fernando; Soto Rifo, Ricardo; Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro; Zeng, Gang; Meng, Weining; González Aramundiz, José Vicente; Goldblatt, David; Acuna González, Pablo Ernesto; Abarca Villaseca, Katia; Bueno Ramírez, Susan Marcela; Kalergis Parra, Alexis Mikes
    Background: The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac® is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. Methods: This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac® separated by two (0-14 schedule) or four weeks (0-28 schedule). 2,302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured. Results: Both schedules exhibited robust neutralizing capacities with the response induced by the 0-28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern between schedules. Stimulation of PBMCs with MPs induced the secretion of IFN-γ and the expression of activation induced markers for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-γ secretion. Conclusions: Immunization with CoronaVac® in Chilean adults promotes robust cellular and humoral immune responses. The 0-28 schedule induced a stronger humoral immune response than the 0-14 schedule.
  • Thumbnail Image
    Item
    Epithelial Cell Culture from Human Adenoids : A Functional Study Model for Ciliated and Secretory Cells
    (2013) González, Claudia; Espinosa de la Fuente, Marisol; Sánchez Dueñas, María Trinidad; Droguett, Karla; Ríos Raggio, Mariana; Fonseca Arrieta, María Ximena; Villalón, Manuel J.
  • Thumbnail Image
    Item
    Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
    (2021) Bueno Ramírez, Susan; Abarca Villaseca, Katia; González Adonis, Pablo Andrés; Gálvez Arriagada, Nicolás Marcelo Salvador; Soto Ramírez, Jorge Andrés; Duarte Peñaloza, Luisa Fernanda; Schultz Lombardic, Bárbara M.; Pacheco, Gaspar A.; González Carreño, Liliana Andrea; Vázquez, Yaneisi; Ríos Raggio, Mariana; Melo González, Felipe; Rivera Pérez, Daniela; Iturriaga, Carolina; Urzúa Acevedo, Marcela del Pilar; Domínguez De Landa, María Angélica; Andrade Parra, Catalina Andrea; Berríos Rojas, Roslye; Canedo Marroquín, Giselda; Covián, Camila
    The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.